Browsing Tag
Johnson & Johnson
109 posts
Heart ablation is moving beyond heat and cold, and the medtech race is getting much bigger
Pulsed field ablation is changing atrial fibrillation treatment by using extremely short electrical pulses to disrupt targeted cardiac cells instead of relying primarily on heat or freezing. Boston Scientific, Medtronic, Abbott Laboratories and Johnson & Johnson now compete across multiple FDA-approved PFA platforms, while new trials are pushing the technology into persistent atrial fibrillation, broader lesion sets and potentially earlier treatment.
Poolbeg Pharma (AIM: POLB) raises £3.5m to fund POLB 001 and oral GLP-1 trials
The discounted placing should fund two potentially value-defining clinical studies through completion, although investors must absorb a larger share base before either programme produces proof-of-concept data.
J&J’s Talvey combination cuts the risk of death by up to 53% in earlier-line multiple myeloma
Johnson & Johnson (JNJ) Talvey combination cut the risk of death by up to 53% in earlier-line multiple myeloma, with FDA and EMA filings underway. Full analysis.
Legend Biotech soars 42% on ASCO data as CAR-T momentum extends from blood cancers toward solid tumors
Legend Biotech soared 42% on ASCO data: a survival readout for myeloma CAR-T CARVYKTI plus early solid-tumor results for LB2102. Big ramp, but still loss-making.
Ligand Pharmaceuticals (LGND) to acquire XOMA Royalty (XOMA) for $739m as biotech royalty consolidation accelerates
Ligand is buying XOMA for $739 million in cash. The real story sits inside a CVR tied to a $19.7 billion Johnson and Johnson royalty fight.
Abbott (NYSE: ABT) showcases four HRS 2026 trials as cardiac rhythm market competition intensifies
Abbott has fresh arrhythmia data, but its stock sits near yearly lows. Can cardiac innovation reset investor confidence?
Johnson & Johnson shows new TECNIS PureSee data at ASCRS 2026 as JNJ eyes deeper ophthalmology upside
Johnson & Johnson unveiled new TECNIS PureSee data at ASCRS 2026. Read how it could reshape cataract surgery growth and JNJ’s medtech outlook.
JNJ’s pasritamig plus docetaxel advances to Phase 3 after strong early results in metastatic castration-resistant prostate cancer
Johnson & Johnson's pasritamig hits 75% PSA response in taxane-naive prostate cancer patients. What Phase 3 means for JNJ's oncology strategy. Read more.
Johnson & Johnson strengthens oncology delivery strategy with EU nod for subcutaneous amivantamab
EU approves subcutaneous amivantamab for EGFR lung cancer. Discover how this could reshape oncology workflows and Johnson & Johnson’s strategy.
Philadelphia jury orders Johnson & Johnson to pay $250,000 in talc powder lawsuit
Johnson & Johnson faces a new talc verdict in Philadelphia. Find out why even a small award still matters for investors and long-term strategy.